M Flanagan1, J Solon1, K H Chang1, S Deady2, B Moran3, R Cahill1, C Shields1, J Mulsow4. 1. National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital, Dublin 7, Ireland. 2. The National Cancer Registry of Ireland, Cork, Ireland. 3. Peritoneal Malignancy Institute, Basingstoke, UK. 4. National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital, Dublin 7, Ireland. Electronic address: jmulsow@mater.ie.
Abstract
INTRODUCTION: Peritoneal metastases (PM) are predominantly seen as a manifestation of intra-abdominal malignancy such as colorectal or ovarian cancer. However, extra-abdominal primary cancer can also metastasise to the peritoneum. Population-based data on the incidence of PM from extra-abdominal cancer is lacking. This study aims to assess the patterns and survival of patients in Ireland with PM from extra-abdominal cancers. METHODS: The National Cancer Registry of Ireland database was interrogated to identify patients diagnosed with PM from extra-abdominal malignancy during the period 1994-2012. Patient demographics and tumour characteristics were analysed. RESULTS: 5791 patients were diagnosed with PM during the study period. Of these, 543 (9%) had an extra-abdominal primary malignancy. Breast (40.8%), lung (25.6%) and melanoma (9.3%) were the most common extra-abdominal cancers to develop PM. The majority of patients with peritoneal metastases of breast origin (75%) were diagnosed at a long interval (median interval 59.5 months; range = 1-485) from the diagnosis of the primary. The median survival from diagnosis of PM was 5.8 months compared with 22.6 months from diagnosis of stage IV disease without peritoneal involvement. Survival in patients with lung cancer and melanoma who developed PM was very poor and similar to that in patients with stage IV disease not involving the peritoneum. CONCLUSION: This is the first population-based study to report the incidence of PM secondary to extra-abdominal malignancy. The most common primary cancers were melanoma, breast and lung cancer. Metastatic disease to the peritoneum was uniformly associated with a poor prognosis.
INTRODUCTION: Peritoneal metastases (PM) are predominantly seen as a manifestation of intra-abdominal malignancy such as colorectal or ovarian cancer. However, extra-abdominal primary cancer can also metastasise to the peritoneum. Population-based data on the incidence of PM from extra-abdominal cancer is lacking. This study aims to assess the patterns and survival of patients in Ireland with PM from extra-abdominal cancers. METHODS: The National Cancer Registry of Ireland database was interrogated to identify patients diagnosed with PM from extra-abdominal malignancy during the period 1994-2012. Patient demographics and tumour characteristics were analysed. RESULTS: 5791 patients were diagnosed with PM during the study period. Of these, 543 (9%) had an extra-abdominal primary malignancy. Breast (40.8%), lung (25.6%) and melanoma (9.3%) were the most common extra-abdominal cancers to develop PM. The majority of patients with peritoneal metastases of breast origin (75%) were diagnosed at a long interval (median interval 59.5 months; range = 1-485) from the diagnosis of the primary. The median survival from diagnosis of PM was 5.8 months compared with 22.6 months from diagnosis of stage IV disease without peritoneal involvement. Survival in patients with lung cancer and melanoma who developed PM was very poor and similar to that in patients with stage IV disease not involving the peritoneum. CONCLUSION: This is the first population-based study to report the incidence of PM secondary to extra-abdominal malignancy. The most common primary cancers were melanoma, breast and lung cancer. Metastatic disease to the peritoneum was uniformly associated with a poor prognosis.
Authors: Eva Mendes Serrao; Ana Maria Costa; Sergio Ferreira; Victoria McMorran; Emma Cargill; Caroline Hough; Ashley S Shaw; Brent O'Carrigan; Christine A Parkinson; Pippa G Corrie; Timothy J Sadler Journal: Insights Imaging Date: 2022-10-04
Authors: Simone Sibio; Giuseppe Sigismondo Sica; Sara Di Carlo; Maurizio Cardi; Alessandra Di Giorgio; Bianca Maria Sollazzo; Paolo Sammartino Journal: J Med Case Rep Date: 2019-08-21
Authors: Daan R Löke; Roxan F C P A Helderman; Jan Sijbrands; Hans M Rodermond; Pieter J Tanis; Nicolaas A P Franken; Arlene L Oei; H Petra Kok; Johannes Crezee Journal: Cancers (Basel) Date: 2020-11-26 Impact factor: 6.639
Authors: Jolene Si Min Wong; Sze Min Lek; Daniel Yan Zheng Lim; Claramae Shulyn Chia; Grace Hwei Ching Tan; Chin-Ann Johnny Ong; Melissa Ching Ching Teo Journal: Front Oncol Date: 2022-01-13 Impact factor: 6.244